Switch theme
Sign up to access all valuation multiples
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
2013
923
LTM Revenue $355M
LTM EBITDA -$140M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Twist Bioscience has a last 12-month revenue (LTM) of $355M and a last 12-month EBITDA of -$140M.
In the most recent fiscal year, Twist Bioscience achieved revenue of $313M and an EBITDA of -$177M.
Twist Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Twist Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $355M | XXX | $313M | XXX | XXX | XXX |
| Gross Profit | $169M | XXX | $133M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | -$140M | XXX | -$177M | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -56% | XXX | XXX | XXX |
| EBIT | -$167M | XXX | -$176M | XXX | XXX | XXX |
| EBIT Margin | -47% | XXX | -56% | XXX | XXX | XXX |
| Net Profit | -$156M | XXX | -$209M | XXX | XXX | XXX |
| Net Margin | -44% | XXX | -67% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Twist Bioscience's stock price is $29.
Twist Bioscience has current market cap of $1.8B, and EV of $1.6B.
See Twist Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.8B | XXX | XXX | XXX | XXX | $-2.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Twist Bioscience has market cap of $1.8B and EV of $1.6B.
Twist Bioscience's trades at 4.8x EV/Revenue multiple, and -9.8x EV/EBITDA.
Equity research analysts estimate Twist Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Twist Bioscience has a P/E ratio of -11.3x.
See valuation multiples for Twist Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | -11.3x | XXX | -9.8x | XXX | XXX | XXX |
| EV/EBIT | -9.5x | XXX | -9.5x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.3x | XXX | -9.3x | XXX | XXX | XXX |
| EV/FCF | -22.7x | XXX | -22.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTwist Bioscience's last 12 month revenue growth is 18%
Twist Bioscience's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Twist Bioscience's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Twist Bioscience's rule of X is 7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Twist Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -49% | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | -31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 99% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Twist Bioscience acquired XXX companies to date.
Last acquisition by Twist Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Twist Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Twist Bioscience founded? | Twist Bioscience was founded in 2013. |
| Where is Twist Bioscience headquartered? | Twist Bioscience is headquartered in United States of America. |
| How many employees does Twist Bioscience have? | As of today, Twist Bioscience has 923 employees. |
| Who is the CEO of Twist Bioscience? | Twist Bioscience's CEO is Dr. Emily M. Leproust, PhD. |
| Is Twist Bioscience publicy listed? | Yes, Twist Bioscience is a public company listed on NAS. |
| What is the stock symbol of Twist Bioscience? | Twist Bioscience trades under TWST ticker. |
| When did Twist Bioscience go public? | Twist Bioscience went public in 2018. |
| Who are competitors of Twist Bioscience? | Similar companies to Twist Bioscience include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Twist Bioscience? | Twist Bioscience's current market cap is $1.8B |
| What is the current revenue of Twist Bioscience? | Twist Bioscience's last 12 months revenue is $355M. |
| What is the current revenue growth of Twist Bioscience? | Twist Bioscience revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Twist Bioscience? | Current revenue multiple of Twist Bioscience is 4.4x. |
| Is Twist Bioscience profitable? | Yes, Twist Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Twist Bioscience? | Twist Bioscience's last 12 months EBITDA is -$140M. |
| What is Twist Bioscience's EBITDA margin? | Twist Bioscience's last 12 months EBITDA margin is -39%. |
| What is the current EV/EBITDA multiple of Twist Bioscience? | Current EBITDA multiple of Twist Bioscience is -11.3x. |
| What is the current FCF of Twist Bioscience? | Twist Bioscience's last 12 months FCF is -$69.7M. |
| What is Twist Bioscience's FCF margin? | Twist Bioscience's last 12 months FCF margin is -20%. |
| What is the current EV/FCF multiple of Twist Bioscience? | Current FCF multiple of Twist Bioscience is -22.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
